A randomised phase III study in advanced oesophageal carcinoma to compare dysphagia in patients treated with radiotherapy versus chemo-radiotherapy.

People with cancer of the oesophagus (gullet) often have trouble swallowing. Radiotherapy can help improve this problem. Using chemotherapy together with radiotherapy may work better but has more side effects. This trial will determine if it is better to use radiotherapy by itself or together with chemotherapy.

Primary Sponsor

Trans Tasman Radiation Oncology Group (TROG)

Collaborating Groups

NCI CTG (ES 2)

Final Accrual

220

Trial Chairperson

Dr Michael Penniment, Royal Adelaide Hospital, SA

Trial Contact

sonya.stephens@health.sa.gov.au

Clinical Trial Registration

Related Post

22 June, 2026

Novel lung cancer radiation therapy approach to be tested in new PRIME-Lung trial

LATEST NEWS: 22 June 2026 In an important step

Facility Alliance Member in Focus
17 June, 2026

TROG Facility Alliance Member in Focus: Radiation Oncology Network, Western Sydney Local Health District

TROG’s Facility Alliance Members (FAM) are the cornerstone of